share_log

B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17

Benzinga ·  01:38  · Ratings

B. Riley Securities analyst Kalpit Patel maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Neutral and lowers the price target from $28 to $17.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment